Academic Journal
MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma
| Title: | MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma |
|---|---|
| Authors: | Lei Lei, Zhiming Jiang, Gu Zhang, Qiaoyuan Cheng, Hongyang Lu |
| Source: | World Journal of Surgical Oncology, Vol 16, Iss 1, Pp 1-6 (2018) |
| Publisher Information: | BMC, 2018. |
| Publication Year: | 2018 |
| Collection: | LCC:Surgery LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | Pulmonary carcinoid, Large-cell neuroendocrine carcinoma, MGMT methylation, 1p/19q co-deletion, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Abstract Background The response to temozolomide (TMZ) treatment in small-cell lung cancer (SCLC) correlated with O(6)-methylguanine -DNA methyltransferase (MGMT) promoter methylation. 1p/19q co-deletion within oligodendroglioma is a responsive predictor for TMZ. Currently, the status of MGMT promoter methylation and 1p/19q co-deletion in pulmonary carcinoid (PC) and large-cell neuroendocrine carcinoma (LCNEC) is not reported. Methods Nine PC [two atypical carcinoids (AC), seven typical carcinoids (TC)] and six LCNEC patients were collected retrospectively. The pyrosequencing and fluorescence in situ hybridization were used to detect the MGMT promoter methylation and 1p/19q co-deletion in surgically resected specimens. Kaplan–Meier analysis was used to assess the rate of disease-free survival (DFS). Results MGMT promoter methylation was found in two (2/6, 15.3%) LCNEC patients but not in any PC patients. Three (3/6, 50%) 1p and two (2/6, 33.3%) 19q single deletions were found in LCNEC patients. One 1p single deletion was found in AC patients. One (1/7, 14.3%) 1p and two (2/7, 28.6%) 19q single deletions were found in TC patients. After a median follow-up of 38 months, three LCNEC patients developed distant metastasis and one patient died of LCNEC disease. The DFS of PC patients was much longer than LCNEC patients (χ 2 = 7.565, P = 0.006). Conclusions MGMT promoter methylation and 1p/19q co-deletion might not be the ideal biomarkers for TMZ treatment in TC/AC patients. Thus, the detection of MGMT promoter methylation and whether it can be used as a medication for TMZ in LCNEC patients necessitates investigation. Furthermore, 1p deletion could be a negative prognostic factor for LCNEC patients. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1477-7819 |
| Relation: | http://link.springer.com/article/10.1186/s12957-018-1413-7; https://doaj.org/toc/1477-7819 |
| DOI: | 10.1186/s12957-018-1413-7 |
| Access URL: | https://doaj.org/article/8e66663c3eb54a10b27bb8f3b406b3b5 |
| Accession Number: | edsdoj.8e66663c3eb54a10b27bb8f3b406b3b5 |
| Database: | Directory of Open Access Journals |
| ISSN: | 14777819 |
|---|---|
| DOI: | 10.1186/s12957-018-1413-7 |
| Published in: | World Journal of Surgical Oncology |
| Language: | English |